Quanterix (NASDAQ:QTRX) vs. TREES (OTCMKTS:CANN) Head-To-Head Review

TREES (OTCMKTS:CANN) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Profitability

This table compares TREES and Quanterix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TREES	N/A	N/A	N/A
Quanterix	-77.14%	-23.96%	-17.86%

Institutional & Insider Ownership

11.3% of TREES shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 45.0% of TREES shares are owned by insiders. Comparatively, 6.8% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

TREES has a beta of -0.65, indicating that its share price is 165% less volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Valuation and Earnings

This table compares TREES and Quanterix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TREES	$13.66 million	0.28	-$3.48 million	($0.02)	-1.66
Quanterix	$138.90 million	1.71	-$107.15 million	($2.52)	-2.01

TREES has higher earnings, but lower revenue than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than TREES, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for TREES and Quanterix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TREES	0	0	0	0	0.00
Quanterix	1	2	1	0	2.00

Quanterix has a consensus price target of $11.33, suggesting a potential upside of 123.98%. Given Quanterix’s stronger consensus rating and higher probable upside, analysts plainly believe Quanterix is more favorable than TREES.

About TREES

Trees Corporation provides products and services to the regulated cannabis industry in the United States. The company operates through Retail and Cultivation segments. It operates a licensed 17,000 square foot light deprivation greenhouse cultivation facility; and retail dispensary store in Englewood, Colorado, as well as retail stores in Portland, Oregon. The company was formerly known as General Cannabis Corp. and changed its name to Trees Corporation in June 2022. Trees Corporation was incorporated in 2013 and is headquartered in Lakewood, Colorado.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.